Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

By Michael Erman and Mariam Sunny Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates, saying the imminent loss of exclusivity on diabetes drug Januvia ...

Merck topped Q4 earnings and revenue estimates, helped by Keytruda and animal health growth, but its 2026 earnings and sales guidance came in below Wall Street expectations.

Merck reported revenue for the fourth quarter was $16.4 billion, an increase of 5% over the fourth quarter of 2024. For the ...

In a landscape defined by rapid change and fierce competition, Merck's recent fourth-quarter earnings report has captured significant attention. The pharmaceutical giant reported earnings and revenue ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Merck struck two deals in the US$10-billion range in 2025, buying Cidara Therapeutics and Verona Pharma in order to pick up ...

Pembrolizumab works by blocking a mechanism that cancer cells use to evade detection by the immune system, according to Drugs ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with the immunotherapy Keytruda (pembrolizumab), has been associated with a 49% ...

Potentially lifesaving treatment for rare cancer patients that costs tens of thousands of dollars will be slashed to just $25 ...